Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials.
Yokote K, Yamashita S, Arai H, Araki E, Matsushita M, Nojima T, Suganami H, Ishibashi S. Yokote K, et al. Among authors: suganami h. Cardiovasc Diabetol. 2021 May 4;20(1):96. doi: 10.1186/s12933-021-01291-w. Cardiovasc Diabetol. 2021. PMID: 33947390 Free PMC article.
Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials.
Tanizawa Y, Kaku K, Araki E, Tobe K, Terauchi Y, Utsunomiya K, Iwamoto Y, Watada H, Ohtsuka W, Watanabe D, Suganami H; Tofogliflozin 004 and 005 Study group. Tanizawa Y, et al. Among authors: suganami h. Expert Opin Pharmacother. 2014 Apr;15(6):749-66. doi: 10.1517/14656566.2014.887680. Epub 2014 Feb 11. Expert Opin Pharmacother. 2014. PMID: 24512053 Clinical Trial.
Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.
Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K, Tanizawa Y, Araki E, Ueda M, Suganami H, Watanabe D; Tofogliflozin 003 Study Group. Kaku K, et al. Among authors: suganami h. Cardiovasc Diabetol. 2014 Mar 28;13:65. doi: 10.1186/1475-2840-13-65. Cardiovasc Diabetol. 2014. PMID: 24678906 Free PMC article. Clinical Trial.
Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial.
Ishibashi S, Yamashita S, Arai H, Araki E, Yokote K, Suganami H, Fruchart JC, Kodama T; K-877-04 Study Group. Ishibashi S, et al. Among authors: suganami h. Atherosclerosis. 2016 Jun;249:36-43. doi: 10.1016/j.atherosclerosis.2016.02.029. Epub 2016 Feb 26. Atherosclerosis. 2016. PMID: 27062408 Free article. Clinical Trial.
Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia.
Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S; K-877 Study Group. Arai H, et al. Among authors: suganami h. Atherosclerosis. 2017 Jun;261:144-152. doi: 10.1016/j.atherosclerosis.2017.03.032. Epub 2017 Mar 24. Atherosclerosis. 2017. PMID: 28410749 Free article. Clinical Trial.
Predictors of the response of HbA1c and body weight after SGLT2 inhibition.
Abe T, Matsubayashi Y, Yoshida A, Suganami H, Nojima T, Osawa T, Ishizawa M, Yamamoto M, Fujihara K, Tanaka S, Kaku K, Sone H. Abe T, et al. Among authors: suganami h. Diabetes Metab. 2018 Mar;44(2):172-174. doi: 10.1016/j.diabet.2017.10.003. Epub 2017 Nov 8. Diabetes Metab. 2018. PMID: 29128289 Clinical Trial. No abstract available.
Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.
Ishibashi S, Arai H, Yokote K, Araki E, Suganami H, Yamashita S; K-877 Study Group. Ishibashi S, et al. Among authors: suganami h. J Clin Lipidol. 2018 Jan-Feb;12(1):173-184. doi: 10.1016/j.jacl.2017.10.006. Epub 2017 Oct 28. J Clin Lipidol. 2018. PMID: 29203092 Free article. Clinical Trial.
Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial.
Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, Nakamura J, Maegawa H, Yoshioka N, Tanizawa Y, Watada H, Suganami H, Ishibashi S. Araki E, et al. Among authors: suganami h. Diabetes Care. 2018 Mar;41(3):538-546. doi: 10.2337/dc17-1589. Epub 2018 Jan 3. Diabetes Care. 2018. PMID: 29298800 Clinical Trial.
Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance.
Matsuba I, Matsuba R, Ishibashi S, Yamashita S, Arai H, Yokote K, Suganami H, Araki E. Matsuba I, et al. Among authors: suganami h. J Diabetes Investig. 2018 Nov;9(6):1323-1332. doi: 10.1111/jdi.12845. Epub 2018 Apr 26. J Diabetes Investig. 2018. PMID: 29603684 Free PMC article. Clinical Trial.
Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.
Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S; K-877 Study Group. Arai H, et al. Among authors: suganami h. J Atheroscler Thromb. 2018 Jun 1;25(6):521-538. doi: 10.5551/jat.44412. Epub 2018 Apr 7. J Atheroscler Thromb. 2018. PMID: 29628483 Free PMC article. Clinical Trial.
63 results